AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PTGX · NASDAQ · Biotechnology

Protagonist Therapeutics (PTGX)

Discovers peptide medicines and earns collaboration economics from partnered ICOTYDE and rusfertide.

$145.07

After hours−0.05 (−0.03%)

At close$145.12(+0.10%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	60	255	4	5	171	28	6	5	7	56	213
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	60	255	4	5	171	28	6	5	7	56	213
	38	37	49	43	46	44	48	48	51	58	60	55
Research & development	31	29	34	34	36	35	36	37	40	46	47	42
	8	8	15	9	10	9	12	11	11	11	13	13
General & administrative	8	8	15	9	10	9	12	11	11	11	13	13
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−38	23	206	−39	−41	127	−19	−42	−46	−50	−4	159
	4	4	4	8	8	7	8	7	7	7	6	6
Interest income	4	4	4	7	8	7	8	7	7	7	6	6
Other non-operating income	0	−4	−4	−8	−8	−7	−8	−7	−7	−7	−6	−6
Income before tax	−34	27	211	−31	−34	134	−12	−35	−39	−44	2	165
Income tax expense	0	0	3	−1	0	2	0	0	0	1	−2	2
Net income from continuing operations	−34	27	207	−31	−33	132	−12	−35	−39	−44	4	163
Net income	−34	27	207	−31	−33	132	−12	−35	−39	−44	4	163
EPS, basic	−$0.58	$0.45	$3.41	−$0.50	−$0.54	$2.11	−$0.19	−$0.55	−$0.62	−$0.69	$0.06	$2.47
EPS, diluted	−$0.58	$0.44	$3.26	−$0.50	−$0.54	$1.98	−$0.19	−$0.55	−$0.62	−$0.69	$0.05	$2.29
Weighted average shares, basic	59	60	61	61	62	62	63	64	64	64	65	66
Weighted average shares, diluted	59	62	64	61	62	66	63	64	64	64	70	71
EBITDA	−37	28	211	−30	−33	134	−11	−34	−39	−43	3	165
Depreciation & amortization	1	1	0	1	1	1	0	0	0	0	0	0
EBIT	−38	27	211	−31	−34	134	−12	−35	−39	−44	2	165